Metabolic syndrome (MS), also known as syndrome X, is associated with high risk for the development of cardiovascular disease (CVD). Since its prevalence is increasing worldwide, a great deal of attention has been directed to this syndrome, in the past several years (1,2). After the identification of the association of metabolic syndrome with increased cardiovascular disease risk, the diagnosis of metabolic syndrome has gained more importance. Currently definition of MS, ATP III or International Diabetes Federation (IDF) criteria, include increased waist circumference, raised triglycerides, low HDL, raised fasting glucose and raised blood pressure (BP), are in use (3,4). Although not well defined, other clinical and biochemical markers associated with MS are known. Non-alcoholic fatty liver disease (NAFLD), accounting for asymptomatic elevation of aminotransferase levels in up to 90 per cent of cases, is the most frequent cause of abnormal liver function tests results (5).